Apoe Mouse shRNA Lentiviral Particle (Locus ID 11816)

CAT#: TL500118V

Apoe - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL500118A virus into HEK293 cells. TL500118A virus was prepared using lenti-shRNA TL500118A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL500118C virus into HEK293 cells. TL500118C virus was prepared using lenti-shRNA TL500118C and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL500118D virus into HEK293 cells. TL500118D virus was prepared using lenti-shRNA TL500118D and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 11816
• Synonyms: AI255918; Apo-E
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: BC028816, BC083351, NM_001305819, NM_001305843, NM_001305844, NM_009696, BC044785
• Summary: This gene encodes a member of the apolipoprotein A1/A4/E family of proteins. This protein is involved in the transport of lipoproteins in the blood. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Homozygous knockout mice for this gene accumulate high levels of cholesterol in the blood and develop atherosclerosis. Different alleles of this gene have been associated with either increased risk or a protective effect for Alzheimer's disease in human patients. This gene maps to chromosome 7 in a cluster with the related apolipoprotein C1, C2 and C4 genes. [provided by RefSeq, Apr 2015]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).